GSK and Gilead Sciences to execute a strategic license agreement for antiviral agentr

Published: 2002-05-15 06:57:00

Updated: 2002-05-15 06:57:00

GlaxoSmithKline says that it signed with Gilead Sciences a strategic license agreement for the commercialization of antiviral agent (adefovir dipivoxil). Adefovir dipivoxil tablet (10mg once daily) for the treatment of chronic hepatitis B virus is now in phase III clinical trials and its applicat...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK